Healthequity (NASDAQ:HQY) had its price objective lifted by research analysts at SunTrust Banks to $70.00 in a research report issued on Tuesday, The Fly reports. The firm currently has a “buy” rating on the stock. SunTrust Banks’ target price would indicate a potential upside of 20.90% from the stock’s current price.
Several other brokerages have also issued reports on HQY. Zacks Investment Research lowered Healthequity from a “buy” rating to a “hold” rating and set a $62.00 price target on the stock. in a research note on Tuesday, February 27th. BidaskClub upgraded Healthequity from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price target on shares of Healthequity in a research note on Thursday, February 22nd. JPMorgan Chase & Co. lowered their price target on Healthequity from $52.00 to $51.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 24th. Finally, Robert W. Baird boosted their price target on Healthequity from $48.00 to $49.00 and gave the company a “neutral” rating in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $59.29.
Healthequity (NASDAQ HQY) opened at $57.90 on Tuesday. Healthequity has a 12 month low of $37.62 and a 12 month high of $60.00. The stock has a market capitalization of $3,603.35, a PE ratio of 78.24, a P/E/G ratio of 2.27 and a beta of 1.46.
Hedge funds have recently added to or reduced their stakes in the company. Zions Bancorporation bought a new stake in shares of Healthequity in the 3rd quarter valued at approximately $119,000. Catalyst Capital Advisors LLC bought a new stake in Healthequity during the 4th quarter worth approximately $149,000. CIBC Asset Management Inc bought a new stake in Healthequity during the 3rd quarter worth approximately $208,000. Two Sigma Securities LLC bought a new stake in Healthequity during the 4th quarter worth approximately $208,000. Finally, Exane Derivatives grew its position in Healthequity by 78.6% during the 4th quarter. Exane Derivatives now owns 4,682 shares of the company’s stock worth $218,000 after acquiring an additional 2,060 shares during the last quarter. Institutional investors own 99.62% of the company’s stock.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.